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Abstract 1-Oleoyl lysophosphatidic acid (LPA) induces trans-
monolayer migration (in vitro invasion) of rat ascites hepatoma
MM1 cells and their morphological changes leading to the
migration. We have previously shown that an LPA analog,
palmitoyl cyclic phosphatidic acid (Pal-cPA), suppresses trans-
monolayer migration of MM1 cells by rapidly increasing the
intracellular cyclic AMP (cAMP) concentration. We report here
that various cAMP-elevating agents, including dibutyryl cAMP,
forskolin, cholera toxin and 3-isobutyl-1-methylxanthine, con-
sistently inhibited LPA-induced transmonolayer migration of
MM1 cells. Moreover, pull-down assays for GTP-bound, active
RhoA demonstrated that the blockage by cAMP-elevating
agents of morphological changes leading to the migration was
probably mediated through inhibiting RhoA activation. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Metastasis is a multistep process that includes detachment
of cancer cells from a primary site, invasion into surrounding
tissues, spread via the circulation, extravasion and prolifera-
tion in distant organs [1,2]. Thus, the ability to invade into
surrounding tissues is a prominent phenotype of cancer cells.
Rat ascites hepatoma (AH130) cells implanted into the peri-
toneal cavity of a Donryu rat invade the peritoneum exten-
sively. The mesothelial cell monolayer covering the perito-
neum is the ¢rst barrier in this process. To evaluate
peritoneal dissemination, we have established an in vitro mod-
el system in which a primary cultured mesothelial cell mono-
layer is penetrated by overlaid AH130 cells (transmonolayer
migration) [3]. This in vitro system is considered to be a good
model for the ¢rst step of cancerous peritonitis. In fact, the
invasive capacity of AH130 cells determined with this in vitro
system correlated well with their invasiveness in vivo in the
peritoneal cavity [4,5]. Using this system, we have already
clari¢ed that rat ascites hepatoma (MM1, a highly invasive
clone of AH130) cells require fetal calf serum (FCS) for the
transmonolayer migration [6]. 1-Oleoyl lysophosphatidic acid
(LPA) could completely substitute for the serum in inducing
the transmonolayer migration [7]. The activity of LPA is not
speci¢c to MM1 cells, but is also observed with mouse mela-
noma B16, human pancreatic adenocarcinoma PSN-1 and
human lung cancer OC-10 cells. A low molecular weight
GTPase, RhoA, plays a pivotal role in this LPA-induced
transmonolayer migration, as shown by the fact that Clostri-
dium botulinum C3 exoenzyme [8], which speci¢cally ADP-
ribosylates and inhibits Rho, strongly suppressed the trans-
monolayer migration [9,10]. The introduction of dominant
active RhoA cDNA into MM1 cells cancelled the FCS or
LPA requirement of MM1 cells for transmonolayer migration
[10]. We have reported that LPA induced polymerization of
actin [11] and increased phosphorylation of myosin light chain
through the Rho-ROCK (Rho-associated kinase) cascade
[12] ; both of these processes are essential for pseudopodia
formation and generation of the motile force in transmono-
layer migration.
LPA is a potent inducer of transmonolayer migration of a
variety of tumor cells. Palmitoyl cyclic phosphatidic acid (Pal-
cPA), a synthetic derivative of PHYLPA [13] (a novel lyso-
phosphatidic acid composed of cyclic phosphate and cyclo-
propane-containing hexadecanoic acid, ¢rst isolated from
myxoamebae of Physarum polycephalum) was tested for its
activity against LPA, because Pal-cPA was reported to inhibit
the cell growth of human ¢broblasts which LPA stimulated.
We have demonstrated that Pal-cPA suppresses LPA-induced
transmonolayer migration [11]. Furthermore, we showed that
Pal-cPA inhibited the LPA-induced actin polymerization that
is essential for morphological changes leading to transmono-
layer migration, possibly through elevating the intracellular
cyclic AMP (cAMP) concentration in MM1 cells [11].
The second messenger cAMP also exerts dramatic e¡ects on
the cytoskeletal architecture. Elevation of the cAMP concen-
tration in a variety of cell types induces loss of actin stress
¢bers and focal adhesions, rounding of cells, and in some
cases detachment from the underlying substratum [14^16].
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Although the mechanism(s) eliciting the e¡ects of cAMP ap-
pear to be complex, recent studies point toward a role for this
cyclic nucleotide in the down-regulation of RhoA [17^21].
Taken together, the above ¢ndings suggest that cAMP-ele-
vating agents may universally inhibit LPA-induced trans-
monolayer migration as well as morphological changes, pos-
sibly through inhibiting RhoA activity.
In the present study, we examined the e¡ects of various
cAMP-elevating agents on LPA-induced transmonolayer mi-
gration and morphological changes in MM1 cells. Moreover,
RhoA activation was assessed as GTP-bound RhoA levels
using the Rhotekin-binding assay [22].
2. Materials and methods
2.1. Chemicals
Bovine serum albumin (BSA, fraction V), 1-oleoyl lysophosphatidic
acid (LPA), ¢bronectin (FN) from bovine plasma, dibutyryl cyclic
AMP (dbcAMP), a membrane-permeable cAMP analog, forskolin
(an adenylate cyclase activator), cholera toxin (a stimulator of heter-
otrimeric G protein Gs) were purchased from Sigma (St. Louis, MO,
USA). LPA was dissolved in PBS supplemented with 0.1% BSA. A
chemiluminescence detection kit (ECL) was purchased from Amer-
sham Pharmacia Biotech, UK. C3 exoenzyme was kindly supplied
by Dr. R. Komagome (Hokkaido University, Sapporo, Japan). Fetal
calf serum (FCS) and 3-isobutyl-1-methylxanthine (IBMX), an inhib-
itor of phosphodiesterase, was from WAKO (Tokyo, Japan).
2.2. Cells and cell culture
The MM1 cell line, which is a highly invasive clone isolated from
parental rat ascites hepatoma AH130 cells, was cultured in suspension
in MEM containing 2-fold concentrated amino acids and vitamins
(modi¢ed MEM) (Nissui, Tokyo, Japan) supplemented with 10%
FCS. Cells were cultured at 37‡C in a humidi¢ed atmosphere of 5%
CO2 in air.
2.3. Transmonolayer migration (in vitro invasion) assay
The assay procedure to measure the in vitro invasive capacity of
tumor cells was essentially the same as described in our previous
report [3]. MM1 cells (2U105 cells) were seeded over a rat mesothelial
cell monolayer (MCL) and cultured in medium containing the materi-
als to be tested. Invasion experiments were started by the addition of
25 WM LPA. Twenty hours later, the supernatant was removed and
the resultant monolayer was ¢xed in situ with 10% formalin. The
number of penetrated single tumor cells and tumor cell colonies (col-
lectively called invasion foci) was counted under a phase-contrast
microscope. The invasive capacity was expressed as the number of
invasion foci per cm2.
2.4. Morphological observation of MM1 cells
Morphological observation of MM1 cells was performed on an
MCL as described above and on an FN-coated dish. A dish of 35
mm diameter was coated with 10 Wg of FN at room temperature for
3 h. An FN-coated dish was blocked with modi¢ed MEM supple-
mented with 1.5% BSA, and then MM1 cells were observed on an
FN-coated dish in the presence of 25 WM LPA in modi¢ed MEM with
or without 1.25 mM dbcAMP at 37‡C under a phase-contrast micro-
scope (Olympus IX70, Tokyo, Japan). To observe the e¡ects of RhoA
inactivation, MM1 cells were pretreated with 10 Wg/ml of C3 exoen-
zyme for 24 h.
2.5. Pull-down assay for GTP-bound RhoA
MM1 cells were washed twice with modi¢ed MEM and incubated
in fresh modi¢ed MEM without serum for 3 h; 25 WM LPA was
added and the cell suspension was centrifuged at the indicated time
after LPA addition, and then cell pellet was lysed in 50 mM Tris^HCl
bu¡er, pH 7.5, containing 1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% SDS, 500 mM NaCl, 10 mM MgCl2, 10 Wg/ml each of
leupeptin and aprotinin, and 1 mM phenylmethylsulfonyl £uoride
(PMSF). Cell lysates were clari¢ed by centrifugation at 13 000Ug at
4‡C for 10 min, and were incubated for 45 min at 4‡C with gluta-
thione beads (Amersham Pharmacia Biotech, UK) coupled with bac-
terially expressed GST^RBD (Rho-binding domain of Rhotekin,
which associates only with GTP-bound, active RhoA) fusion protein
(provided by Dr. M. Schwartz, Scripps Research Institute, USA). The
beads were washed four times with 50 mM Tris^HCl bu¡er, pH 7.5,
containing 1% Triton X-100, 150 mM NaCl, 10 mM MgCl2, 10 Wg/ml
each of leupeptin and aprotinin, and 1 mM PMSF. Activated RhoA
bound to beads or total RhoA in cell extracts was detected by West-
ern blotting using a monoclonal antibody against RhoA (Santa Cruz
Biotechnology, CA, USA).
3. Results
3.1. Inhibition of transmonolayer migration by various
cAMP-elevating agents
We have already reported that LPA induces the transmo-
nolayer migration of MM1 cells through a mesothelial cell
monolayer [7]. An LPA analogue, Pal-cPA, e¡ectively inhibits
the transmonolayer migration, with approximately 93.8% in-
hibition at the concentration of 25 WM [11]. Because Pal-cPA
induced a rapid increase of the cAMP concentration in MM1
cells, this inhibition might be ascribed to an increased level of
intracellular cAMP [11]. In the present study, we investigated
the e¡ects of various cAMP-elevating agents on the transmo-
nolayer migration of MM1 cells. As shown in Table 1, all of
the cAMP-elevating agents used in this study, i.e. dbcAMP,
forskolin, cholera toxin and IBMX, strongly suppressed LPA-
induced transmonolayer migration of MM1 cells. These re-
sults suggest that transmonolayer migration of MM1 cells is
suppressed by increasing the intracellular cAMP concentra-
tion.
3.2. The e¡ects of dbcAMP on the LPA-induced morphological
changes leading to the transmonolayer migration of MM1
cells
We have reported that LPA induces transient polymeriza-
tion of actin through RhoA activation and that this polymer-
ization of actin is suppressed by Pal-cPA or dbcAMP [11]. We
have also shown that cooperation of LPA with the interaction
between FN and L1 integrin mediated the formation of focal
adhesions necessary for the transmonolayer migration of
MM1 cells [23].
When MM1 cells on an FN-coated dish were stimulated by
LPA, they showed a unidirectionally extended fusiform shape
with the nucleus localized in one end (equivalent to pseudo-
podia formation) and the fusiform-shaped cells migrated with
the nuclear end as the moving front, as seen under a phase-
contrast microscope (Fig. 1a). LPA induced the same mor-
phological changes in MM1 cells that were seeded on an
MCL (Fig. 1b). These observations suggest that the morpho-
logical changes to the fusiform shape are essential for trans-
monolayer migration of MM1 cells.
Table 1
cAMP-elevating agents inhibit the transmonolayer migration of
MM1 cells
cAMP-elevating agents Inhibition of transmonolayer
migration in vitro (%)
dbcAMP (1.25 mM) 93.0
Cholera toxin (1 Wg/ml) 86.1
Forskolin (10 WM) 97.1
IBMX (1 mM) 96.0
dbcAMP, dibutyryl cyclic AMP; IBMX, 3-isobutyl-1-methylxan-
thine.
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Since dbcAMP inhibited actin polymerization [11], the ef-
fects of dbcAMP on the LPA-induced morphological changes
of MM1 cells were investigated. Fig. 2a shows the fusiform-
shaped MM1 cells induced by LPA on an FN-coated dish.
The morphological changes to the fusiform shape were re-
markably suppressed by addition of dbcAMP (Fig. 2b).
When MM1 cells that had been pretreated with C3 exoenzyme
to inactivate RhoA GTPase were seeded on an FN-coated
dish and stimulated by LPA, neither fusiform-shaped cells
(Fig. 2c), nor the transmonolayer migration were observed,
as described previously [9,10]. Thus, MM1 cells treated with
dbcAMP and those treated with C3 exoenzyme showed a
similar cell shape.
3.3. Inhibition of RhoA activation by cAMP-elevating agents
Since dbcAMP inhibited actin polymerization [11] and mor-
phological changes to the fusiform shape (Fig. 2b), it was
suggested that dbcAMP might inactivate RhoA. Therefore,
we measured the intracellular levels of the GTP-bound, active
form of RhoA by the pull-down assay system [22]. The Rho-
binding domain of Rhotekin [24], which is known to associate
only with the GTP-bound form of RhoA, was fused to glu-
tathione S-transferase, the resultant fusion protein was incu-
bated with cell extracts, and the bound RhoA was detected by
Western blotting. As shown in Fig. 3a, the level of GTP-
bound RhoA was elevated transiently after the addition of
LPA and reached the peak level at 15 min after LPA addition,
Fig. 1. Morphological changes of MM1 cells stimulated with LPA. MM1 cells (3U105) seeded on an FN-coated dish (a) or on a mesothelial
cell monolayer (MCL) (b) were cultured with 25 WM LPA. Phase-contrast micrographs are shown at the indicated time points after LPA addi-
tion. Scale bar: 10 Wm.
FEBS 24234 26-10-00
M. Mukai et al./FEBS Letters 484 (2000) 69^73 71
whereas dbcAMP and other cAMP-elevating agents decreased
the level of active RhoA (Fig. 3b). Since the total amount of
RhoA in each lysate was almost constant, cAMP-elevating
agents inhibited RhoA activation.
4. Discussion
It is important for understanding the molecular mechanisms
of cancer invasion and metastasis to analyze the signal trans-
duction pathways leading to cell migration. Using our in vitro
invasion model, we have already reported that a low molec-
ular weight GTPase, RhoA, plays an important role in LPA-
induced transmonolayer migration [9,10].
LPA induces the transmonolayer migration of MM1 cells,
while Pal-cPA, an analogue of LPA, suppresses it [11]. Pal-
cPA also suppresses the transmonolayer migration of mouse
melanoma cells (B16), human pancreatic adenocarcinoma
cells (PSN-1), and human lung cancer cells (OC-10), which
require LPA for transmonolayer migration. Transmonolayer
migration of human ¢brosarcoma cells (HT-1080), which do
not require LPA for transmonolayer migration, was also sup-
pressed by Pal-cPA. We have previously suggested that this
suppression may be due to the elevation of intracellular
cAMP concentration rather than to the competition for
LPA receptor [11].
The mechanisms through which cAMP regulates various
cellular functions still remain controversial. Tanaka et al.
demonstrated that cAMP suppresses in vitro invasion of
HT-1080 cells using Boyden chamber assays [25]. They sug-
gested that this suppression of in vitro invasion is due to the
inhibition of type IV collagenolytic activity resulting from
increased levels of the mRNAs and proteins of TIMPs.
Laundanna et al. have shown that cAMP abrogates GDP/
GTP exchange of RhoA, resulting in the inhibition of RhoA
function [18]. More recently, Busca et al. have demonstrated
that the cAMP-induced di¡erentiation of melanoma cells is
mediated by the inhibition of RhoA through the suppression
of Rac [19]. These investigators suggested that cAMP regu-
lates RhoA function by a mechanism that acts upstream of
RhoA.
Fig. 2. Suppression of LPA-induced morphological changes by treatment with dbcAMP or C3. MM1 cells on an FN-coated dish were stimu-
lated with 25 WM LPA (a). MM1 cells on an FN-coated dish were treated with 1.25 mM dbcAMP in the presence of 25 WM LPA (b). MM1
cells were pretreated with 10 Wg/ml of C3 exoenzyme for 24 h, then washed with modi¢ed MEM, and incubated on an FN-coated dish in the
presence of 25 WM LPA (c). Phase-contrast images of the cells are shown. Scale bar: 10 Wm.
Fig. 3. Activation of cellular RhoA in response to stimulation with LPA. MM1 cells were incubated in suspension in the absence of serum for
3 h, and subsequently cultured in the presence of 25 WM LPA alone (a) or 25 WM LPA plus various cAMP-elevating agents (1.25 mM
dbcAMP, 10 WM forskolin or 1 mM IBMX) (b). Cell lysates were prepared from MM1 cells treated with LPA for the indicated periods. The
lysates were then incubated with GST^RBD beads. After extensive washing, the bound protein and total RhoA in the cell lysate were analyzed
by Western blotting with a monoclonal anti-RhoA antibody.
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Recently, Schwarz et al. have developed a new method for
determination of the level of activated RhoA [22], the utilizing
Rho-binding domain of Rhotekin [24]. Using this method,
O’Connor et al. found a speci¢c integrin-mediated pathway
of RhoA activation that is regulated by cAMP and that func-
tions in lamellae formation and migration [26]. We also dem-
onstrated, employing this method, that cAMP-elevating
agents suppressed RhoA activation in transmonolayer migra-
tion of MM1 cells (Fig. 3b). Pal-cPA also suppressed RhoA
activation (data not shown).
Lang et al. reported that RhoA is phosphorylated on Ser-
188 by PKA, which acts downstream of cAMP, and that this
phosphorylation of RhoA increases its interaction with gua-
nine nucleotide dissociation inhibitor (GDI) even in its GTP-
bound state. They suggested that the translocation of phos-
phorylated RhoA GTP from membrane to cytosol by its bind-
ing to GDI terminates RhoA signaling by preventing its in-
teraction with downstream e¡ectors, independently of its
cycling from GTP to GDP [20]. It remains to be clari¢ed
whether RhoA is phosphorylated by PKA in MM1 cells
treated with cAMP-elevating agents. Further studies of this
subject will be useful for understanding the molecular mech-
anisms of cancer invasion and metastasis. In conclusion, we
showed here that cAMP-elevating agents blocked morpholog-
ical changes leading to transmonolayer migration, probably
through inhibiting RhoA activation.
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